Rein Therapeutics Inc（RNTX）财务数据RNTXRein Therapeutics Inc

Evaluating the bottom line, Rein Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -753.55%, provide a clear picture of how effectively RNTX converts its operational activities into shareholder value.

In the context of the broader market, RNTX competes directly with industry leaders such as VRCA and ATHE. With a market capitalization of $52.62M, it holds a significant position in the sector. When comparing efficiency, RNTX's gross margin of N/A stands against VRCA's 85.02% and ATHE's 100.00%. Such benchmarking helps identify whether Rein Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Rein Therapeutics has faced significant losses, with a net income of -63.69% over the past year and a current ratio of 4.27, indicating strong liquidity despite ongoing operational losses.